O-304

Pan-AMPK Activation via PP2C Inhibition#

O-304 is a first-in-class pan-AMPK activator — meaning it activates all twelve possible αβγ isoform combinations of the AMP-activated protein kinase complex, rather than selectively targeting one β-subunit like the ADaM-site allosteric activators (A-769662, MK-8722, PF-739). Mechanistically, O-304 does not bind AMPK directly. Instead, it inhibits protein phosphatase 2C (PP2C / PPM1)-mediated dephosphorylation of pAMPK at Thr172, the activation residue. The result is sustained elevation of the phosphorylated, active form of AMPK across every tissue that expresses it — muscle, liver, heart, kidney, vasculature.

This is the same downstream signal that exercise, fasting, and metformin all converge on, which is why O-304 is classified as an exercise mimetic rather than a stimulant or a hormone.

"In both mice and T2D patients, O304 increased AMPK activation, enhanced glucose uptake and improved microvascular perfusion, with reduced fasting plasma glucose and blood pressure observed following treatment." — Steneberg P. et al. JCI Insight, 2018

For the bodybuilding and looksmaxxing audience, the practical hook is that AMPK activation drives insulin-independent GLUT4 translocation in skeletal muscle — i.e., glucose uptake into muscle without needing an insulin signal. That is the basis of the recomp and on-cycle glucose-control use cases.

Mild Mitochondrial Uncoupling#

A 2025 mechanistic study identified a second, complementary mechanism: O-304 behaves as a mild mitochondrial uncoupler, increasing oxygen consumption rate and slightly lowering mitochondrial membrane potential in vascular smooth muscle and hepatocytes. The resulting dip in the cellular ATP/AMP ratio is itself a canonical upstream AMPK trigger, so the two mechanisms reinforce one another in a feed-forward loop.

"O304 increases mitochondrial oxygen consumption and slightly reduces mitochondrial membrane potential, acting as a mild uncoupler and resulting in both vasorelaxation and extended lifespan in C. elegans." — Zhang Y.D. et al. Chemico-Biological Interactions, 2025

This is a substantially gentler uncoupling profile than DNP — there is no documented hyperthermia, no metabolic-rate spike that requires temperature monitoring, and no tight therapeutic window. The uncoupling contribution is what links O-304 to the C. elegans lifespan-extension data and to its endothelium-independent vasorelaxant effect.

Fatty-Acid Oxidation and Hepatic Lipid Remodeling#

Downstream of AMPK activation, O-304 shifts substrate selection toward fat oxidation by phosphorylating ACC (acetyl-CoA carboxylase), which lowers malonyl-CoA and removes the brake on CPT-1-mediated mitochondrial fatty-acid import. Simultaneously, AMPK suppresses SREBP-1c, throttling de novo lipogenesis in the liver. The net result is more fat burned, less fat made.

"Oral administration of ATX-304 led to increased fatty acid oxidation, decreased hepatic steatosis and fibrosis, and reduced body fat mass and cholesterol in MASLD models." — López-Pérez A. et al. JCI Insight, 2025

This is the molecular basis for the post-cycle liver-cleanup protocol — heavy oral AAS runs leave behind hepatic steatosis and a wrecked lipid panel, and O-304 hits exactly the pathways that need to be reversed.

Cardiac and Microvascular Effects#

In aged mice, chronic O-304 administration reproduces a phenotype that looks remarkably like endurance training: higher stroke volume, larger end-diastolic volume, lower resting heart rate, and improved exercise capacity. In the Phase IIa T2D trial, calf-muscle microvascular perfusion improved measurably alongside reductions in blood pressure.

"Chronic O304 treatment in aged mice resulted in improved glucose tolerance, increased cardiac stroke volume and end-diastolic volume, and reduced resting heart rate—resembling the cardiac phenotype seen with exercise training." — Ericsson M. et al. Communications Biology, 2021

Importantly, O-304 has not reproduced the cardiac hypertrophy that killed MK-8722's development program — likely because MK-8722's β1-selective allosteric activation hyperactivated γ2-containing AMPK in cardiomyocytes, whereas O-304's PP2C-inhibition mechanism produces a more physiological pAMPK signal. For users stacking O-304 with on-cycle AAS, the BP-lowering and microvascular benefits are functionally additive with telmisartan and low-dose tadalafil.

mTOR Suppression and AMPK-Dependent Renoprotection#

AMPK activation suppresses mTORC1 and induces autophagy — the same axis rapamycin hits from the opposite direction. This is the mechanistic basis for the lifespan extension observed in C. elegans and for the renoprotective effect documented against cisplatin nephrotoxicity.

"ATX-304 protected against cisplatin-induced acute kidney injury via AMPK-dependent metabolic reprogramming, as demonstrated by loss of protection in AMPK knockout cells." — Katerelos M. et al. Biomedicine & Pharmacotherapy, 2024

The AMPK-knockout rescue experiment matters: it proves the protective effect is AMPK-dependent rather than an off-target artifact. For the longevity-stack reader, this is the molecular handle that makes O-304 a credible companion to rapamycin, NMN, and MOTS-c rather than a redundant addition — it activates the same downstream autophagy and metabolic-reprogramming machinery through an upstream node those other compounds do not touch.

Common (most users)#

• Mild GI upset (loose stools, nausea, transient bloating) — the most frequently reported effect, shared with metformin and other AMPK activators. Mitigation: split the daily dose (50mg AM + 50mg mid-day rather than 100mg in one shot), administer with a small amount of food rather than fully fasted, and ramp from 50mg to 100mg over two weeks rather than jumping.
• Mild blood-pressure reduction — usually desirable, but worth tracking. Subjects in the Phase IIa T2D trial showed reduced fasting plasma glucose and reduced blood pressure on O-304. Mitigation: home BP cuff, weekly readings. Users already running telmisartan + tadalafil should expect additive effects and may need to drop antihypertensive dosing rather than add to it.
• Lower resting heart rate — consistent with the aged-mouse cardiac phenotype (reduced resting HR, increased stroke volume). Generally a positive marker, not a problem. Mitigation: none required unless resting HR drops below the user's baseline by more than ~10 bpm or symptoms appear.
• Mild fatigue or "flat" feeling in the first week — the mitochondrial uncoupling effect documented by Zhang et al. (2025) slightly reduces mitochondrial membrane potential, and some users notice a brief adaptation period. Mitigation: start at 50mg/day for the first 7–10 days, then escalate.

Uncommon (dose-dependent or individual)#

• Hypoglycemia symptoms (shakiness, sweating, brain fog) — appears at higher doses in subjects also running insulin, sulfonylureas, or aggressive carb restriction. Pan-AMPK activation enhances insulin-independent glucose uptake into muscle, which is additive to whatever else is on board. Back off if fasting glucose drops below ~70 mg/dL or if symptoms appear in the fasted-cardio window. Bloodwork: fasting glucose, HbA1c at week 8.
• Persistent GI complaints past week 3 — if dose-splitting and food pairing do not resolve symptoms, the protocol calls for dropping back to 50mg/day or pausing for a week before re-titrating.
• Lipid panel shifts — generally favorable in the MASLD model work (reduced total cholesterol), but individual response varies. Bloodwork: full lipid panel at baseline, 8 weeks, and 12 weeks.
• Liver enzyme drift — not reported as a signal in the published clinical work, but any 8–12 week oral compound warrants ALT/AST monitoring, particularly when stacked behind oral AAS.

"In both mice and T2D patients, O304 increased AMPK activation, enhanced glucose uptake and improved microvascular perfusion, with reduced fasting plasma glucose and blood pressure observed following treatment." — Steneberg et al., JCI Insight (2018)

Rare but serious#

• Symptomatic hypoglycemia when stacked with exogenous insulin or sulfonylureas during fasted cardio — mechanistically predictable, not anecdotal. Warning signs: tremor, cold sweat, confusion, palpitations. Discontinue the stack combination and re-evaluate.
• Theoretical cardiac hypertrophy concern — the comparator pan-AMPK activator MK-8722 produced cardiac hypertrophy in non-human primates via γ2-AMPK hyperactivation, which is what stalled its development. O-304 has not shown this signal in published rodent work — Ericsson et al. (2021) found the opposite, with improved cardiac stroke volume and end-diastolic volume in aged mice — but long-term human cardiac imaging data do not yet exist. Warning signs: unexplained dyspnea on exertion, palpitations, exercise intolerance. Subjects with a family history of HCM should obtain a baseline echo before initiation.

"Chronic O304 treatment in aged mice resulted in improved glucose tolerance, increased cardiac stroke volume and end-diastolic volume, and reduced resting heart rate—resembling the cardiac phenotype seen with exercise training." — Ericsson et al., Communications Biology (2021)

Hard contraindications#

• Concurrent exogenous insulin or sulfonylureas combined with fasted training or skipped meals — stacked hypoglycemia risk. The protocol does not run alongside aggressive insulin protocols without continuous glucose monitoring.
• Pre-existing left ventricular hypertrophy or hypertrophic cardiomyopathy — given the pan-AMPK class signal from MK-8722, subjects with structural cardiac hypertrophy are excluded from the protocol pending long-term human cardiac data on O-304 specifically.
• Pregnancy and lactation — no human reproductive data exist, and AMPK is a major developmental regulator. Hard line.
• Active severe renal or hepatic impairment — despite the renoprotective signal in cisplatin-AKI models (Katerelos 2024) and the MASLD-reversal signal (López-Pérez 2025), neither finding licenses use in subjects with established organ failure outside a clinical setting.

Gender, fertility, and PCT considerations#

O-304 is a non-hormonal small molecule with no HPTA interaction, no aromatization, no 5-AR activity, and no androgen-receptor binding. No PCT is required. The same 50–150 mg/day dose range applies across the full subject pool — there is no rationale for separate male and female ladders. Women of reproductive age should treat the pregnancy/lactation contraindication as hard, but otherwise face no virilization or cycle-disruption concerns. For users running a hair stack, an AAS cycle, or a tadalafil/finasteride protocol, O-304 layers cleanly without adding hormonal noise — its interactions are metabolic (insulin, sulfonylureas, antihypertensives), not endocrine.